OUR PIPELINE
MAKING
THE GREAT,
GREATER
We analyze the unmet needs of patients—continuously looking for ways to further improve therapies for those who need them. To help realize this goal, our teams have been hard at work to grow our portfolio of oncology, critical care, and orphan disease treatments through the development of biologics and small molecules.
OUR PORTFOLIO AND PIPELINE CURRENTLY INCLUDES
RYANODEX® (dantrolene sodium) for Injectable Suspension
Learn more about RYANODEX and approved indications
Nerve-Agent Induced Brain Damage Investigational Indication
VASOPRESSIN INJECTION
PEMFEXY® (pemetrexed injection)
BELRAPZO® (bendamustine hydrochloride injection)
BENDEKA® (bendamustine hydrochloride) Injection
Learn more about BENDEKA and approved indications in the full Prescribing Information
Fulvestrant
Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer, Who Have Gone Through Menopause and Have Not Been Previously Treated with Endocrine Therapy Investigational Indication
HR-Positive Advanced Breast Cancer, Who Have Gone Through Menopause and Whose Disease Has Progressed After Endocrine Therapy Investigational Indication
HR-Positive, HER2-Negative Advanced Breast Cancer or Breast Cancer That Has Spread to Other Parts Of The Body (Metastatic), in Combination With Palbociclib or Abemaciclib in Women Whose Disease Has Progressed After Endocrine Therapy Investigational Indication
